“Dabigatran was significantly associated with a higher risk of MI or ACS than that seen with agents used in the control group” (dabigatran, 237 events of 20,000 [1.19 percent] vs. control, 83 ...

Once again dabigatran (Pradaxa) has raised the wrath of the critics. Several articles and an editorial published today in The BMJ raise more questions and concerns about the drug, which is the ...

By 72 hours after the administration of idarucizumab, antithrombotic therapy was restarted in 69 of the 301 patients in group A (22.9%), with 10.1% of those patients receiving dabigatran, and in ...

Dabigatran will be sold under the brand name Pradaxa. Analysts are predicting the drug will be a blockbuster, with sales reaching an estimated $2.5 billion annually by 2020.

Current guidelines have no recommendations on the utilization of novel oral anticoagulants, such as dabigatran, for the prevention of thromboembolic events in patients with mechanical heart valves ...

Treatment with the 150-mg twice daily do se of dabigatran is equally safe and effective in patients with permanent, persistent, and paroxysmal atrial fibrillation. The 110-mg dose, however, was ...

Anticoagulation with uninterrupted dabigatran was associated with fewer bleeding complications compared with uninterrupted warfarin among patients undergoing ablation for atrial fibrillation ...

Specific reversal agents for non–vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.We ...